SSY Group (2005) AI Stock Analysis

SSY Group Limited has confirmed that the trustee of its Restricted Share Award Scheme purchased 400,000 shares on the open market on 28 October 2026, representing about 0.014% of the company’s issued share capital. The purchase, funded entirely...

SSY Group Limited reported unaudited turnover of approximately HK$3,520 million for the nine months ended 30 September 2026, up 13.5% year on year, driven mainly by recovery in its intravenous infusion solution and bulk pharmaceuticals businesses. Gr...

SSY Group Limited has secured approval from China’s National Medical Products Administration for its Labetalol Hydrochloride as a bulk drug, complementing its previously approved injection preparation used primarily for treating hypertension. T...

SSY Group Limited has obtained approval from China’s National Medical Products Administration to produce and register its preservative-free Sodium Cromoglicate Eye Drops 2% in single-dose packaging, an over-the-counter treatment for spring alle...

SSY Group Limited has received approval from China’s National Medical Products Administration to produce and register its Nimodipine Oral Solution, classified as a type 3 chemical drug that meets consistency evaluation standards. The product ta...

SSY Group has reshaped its senior leadership, appointing veteran executive Mr. Wu Hengyao as an executive director with effect from 28 September 2026 while he continues to serve as president of its key subsidiary Shijiazhuang No. 4 Pharmaceutical. Hi...

SSY Group Limited announced the current composition of its board of directors, confirming Qu Jiguang as executive director, chairman and chief executive officer, supported by a team of executive, non-executive and independent non-executive directors....

SSY Group Limited has obtained Chinese regulatory approval for its Ziprasidone Mesilate as a bulk drug for market preparations, a compound used primarily to treat acute agitation symptoms in patients with schizophrenia. The registration by the Nation...

SSY Group Limited has received approval from China’s National Medical Products Administration to produce and register Letermovir Injection, classified as a type 4 chemical drug that has passed consistency evaluation. The intravenous therapy tar...

SSY Group Limited has announced that the trustee of its Restricted Share Award Scheme purchased 1,000,000 shares on the open market on 3 September 2026, funded by the company’s internal resources, at an average price of about HK$2.754 per share...

SSY Group Limited has announced that the trustee of its Restricted Share Award Scheme purchased 1,200,000 shares on the open market on 2 September 2026, funded by the company’s internal resources. The purchase represents approximately 0.041% of...

SSY Group Limited has secured approval from China’s National Medical Products Administration for the consistency evaluation of the quality and efficacy of its Diltiazem Hydrochloride Tablets, its third such approval among its PRC entities. The...

SSY Group Limited has expanded its restricted share award scheme by funding the purchase of 1,000,000 shares on the open market, to be held in trust for selected participants under the plan. The acquisition, completed on 1 September 2026 at an averag...

SSY Group Limited has disclosed that the trustee of its restricted share award scheme purchased 900,000 shares on the open market on 31 August 2026, funded entirely by the company’s internal resources and representing about 0.030% of its issued...

SSY Group has secured approval from China’s National Medical Products Administration for production and registration of its Gadobutrol Injection, a next-generation macrocyclic MRI contrast agent for adults and children, completing an integrated...

SSY Group reported steady growth for the six months to 30 June 2026, navigating a complex macroeconomic backdrop and ongoing reforms in China’s pharmaceutical sector, including centralised procurement and shifting healthcare insurance policies....

SSY Group Limited has declared an interim ordinary cash dividend of HKD 0.055 per share for the six months ended 30 June 2026, payable in Hong Kong dollars without withholding tax. The ex-dividend date is set for 10 September 2026, with the record da...

SSY Group Limited, a China-focused pharmaceutical manufacturer, has expanded its neurology franchise built around ozagrel-based treatments used in hospital and specialist settings. The company previously marketed ozagrel sodium chloride intravenous i...

SSY Group Limited has received approval from China’s National Medical Products Administration for production and registration of its Vitamin K1 Injection, which has passed consistency evaluation. The injectable is indicated for treating and pre...

SSY Group Limited has scheduled a board meeting for 26 August 2026 to approve the unaudited interim results for the six months ended 30 June 2026. The meeting will also review whether to recommend an interim dividend, highlighting the company’s...

SSY Group Limited has secured approval from China’s National Medical Products Administration for its Ziprasidone Hydrochloride to be registered as a bulk drug used in market preparations, expanding its presence in second-generation antipsychoti...

SSY Group has secured approvals from China’s National Medical Products Administration for four new drugs, all deemed to have passed consistency evaluation, marking an expansion of its regulated product line. The newly cleared products include a...

SSY Group Limited announced that all 13 products with 16 specifications it submitted for the twelfth batch of China’s National Centralised Medicines Procurement were successfully selected, covering a range of tablets, capsules and injections us...